Discover and read the best of Twitter Threads about #ASCOConnection
Most recents (1)
Analyzing this study of defibrotide in VOD after transplant from Spain @amarkelkar @AkshaySharmaMD @hmgcoa2
➡️Link:tandfonline.com/doi/full/10.10… (accepted, not final)
➡️ Price data from Spain with €2019
➡️ FDA approved (March 30, 2016): fda.gov/drugs/resource…
➡️Link:tandfonline.com/doi/full/10.10… (accepted, not final)
➡️ Price data from Spain with €2019
➡️ FDA approved (March 30, 2016): fda.gov/drugs/resource…
➡️ VOD (~15% ,all types): a bad complication with high mortality (severe type, historically >80%)
➡️ Diagnosis &grading(see tables👇) (nature.com/articles/bmt20…)
➡️Authors question: is defibrotide cost-effective using price input from Spain (note this is likely different from US)
➡️ Diagnosis &grading(see tables👇) (nature.com/articles/bmt20…)
➡️Authors question: is defibrotide cost-effective using price input from Spain (note this is likely different from US)
➡️ Simplified definitions:
1⃣ Cost-effectiveness analysis(CEA) is usually measured by incremental cost-effectiveness ratio (ICER) and it establishes how much extra has to be paid for extra benefit.
1⃣ Cost-effectiveness analysis(CEA) is usually measured by incremental cost-effectiveness ratio (ICER) and it establishes how much extra has to be paid for extra benefit.
